The US Food and Drug Administration (FDA) today authorized intradermal administration of the Jynneos vaccine for the treatment of monkeypox. The process, approved specifically for high-risk patients, was passed under the administration's Emergency Use Authorization. It follows the decision on August 4 by the US Department of Health and Human Services to declare monkeypox a public health emergency. Intradermal administration will allow providers to get five doses out of a one-dose vial.
Medscape Medical News will update this article as more information becomes available.
Lead Image: Mario Tama/Getty Images
Cite this: FDA Authorizes Intradermal Use of Jynneos Vaccine for Monkeypox - Medscape - Aug 09, 2022.